Streetbeat News

Price Targets

TXG

Over the past three months, 11 analysts have provided diverse ratings for 10x Genomics (NASDAQ:TXG), ranging from bullish to bearish. The average 12-month price target has dropped by 35% to $26.0. Analysts have recently lowered their price targets and ratings, reflecting a cautious outlook on the company's future performance.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 7:01 pm

WMT

In the past three months, 36 analysts have provided ratings for Walmart (NYSE:WMT), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 8.51% to $74.06. Recent analyst actions predominantly involve raising price targets and ratings, reflecting a positive outlook on Walmart's performance.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 7:01 pm

SATS

EchoStar shares are trading higher after UBS raised its price target on the stock from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 7:01 pm

GOLD

NEM

Barrick Gold Corp. (NYSE:GOLD) CEO Mark Bristow attributes high gold prices to geopolitical instability rather than inflation. Despite strong financial performance in Q2, Bristow believes the market undervalues Barrick's gold and copper assets. The company's shares have risen following the announcement, with analysts raising price targets. Barrick's joint venture with Newmont Corporation (NYSE:NEM) and its expanding copper business are highlighted as key assets.

Portfolio Pulse from Matt Whittaker

August 13, 2024 | 6:59 pm

HAE

JMP Securities analyst David Turkaly has reiterated a Market Outperform rating on Haemonetics (NYSE:HAE) and maintained a price target of $125.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:41 pm

LQDA

Needham analyst Serge Belanger reiterates a Buy rating on Liquidia (NASDAQ:LQDA) and maintains a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:37 pm

ACRV

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:35 pm

LXRX

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:31 pm

JSPR

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Jasper Therapeutics (NASDAQ:JSPR) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:29 pm

INKT

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on MiNK Therapeutics (NASDAQ:INKT) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:28 pm